Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India
| Autor: | Rekha V. Kumar, K C Lakshmaiah, Dipti Panwar, Champaka Gopal, Geetha Vikram Patil Okaly, Chennagiri Srinivasmurthy Premalata, Suma Mysore Narayana, Usha Amirtham, S. Krishnamurthy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Estrogen receptor ORIGINAL ARTICLE: Breast Cancer human epidermal growth factor receptor-2 lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Progesterone receptor Medicine Triple-negative breast cancer business.industry Incidence (epidemiology) Retrospective cohort study hormone receptor lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology Hormone receptor 030220 oncology & carcinogenesis immunohistochemistry triple-negative breast cancer Immunohistochemistry business |
| Zdroj: | South Asian Journal of Cancer South Asian Journal of Cancer, Vol 7, Iss 1, Pp 7-10 (2018) |
| ISSN: | 2278-4306 2278-330X |
| Popis: | Aim: The aim of the study was to analyze the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status over 7 years in South Indian women with breast cancer. Further analysis of a subgroup was done to study clinically defined subtypes and the role of preanalytical factors in needle core biopsies (NCBs) and excised specimens. Materials and Methods: This was a retrospective study from January 2010 to December 2016. Patients diagnosed with invasive breast cancer and available immunohistochemistry (IHC) reports of ER, PR, and HER2 status were analyzed. The cases for the year 2016 were analyzed further to observe the impact of preanalytical factors on the IHC staining patterns and surrogate status. Results: A total of 5436 patients were included with a median age of 48 years. Among these, 65% were ≤ 55 years. The overall incidence of hormone receptor (HR)-positive patients was 48%; HER2 positive, 15%; and triple-negative breast cancer (TNBC), 37%. The incidence of HR positive, HER2 positive, and TNBC were 45%, 16%, and 39% and 53%, 13%, and 34% in patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|